ArticleFrontiers in neuroscience2026
Multimodal DeepSurv model with SHAP-based interpretation for predicting local failure in patients with brain metastases undergoing hypofractionated stereotactic radiotherapy.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Local Progression-Free Survival (LPFS) is an important clinical endpoint following hypofractionated stereotactic radiotherapy (HSRT) for brain metastases (BMs). However, accurate prediction of local failure risk remains challenging because conventional clinical factors do not fully capture tumor heterogeneity. Therefore, we aimed to develop and validate an explainable radiomics-based deep learning survival model to predict LPFS after HSRT and identify patients at elevated risk of local failure. Methods: This retrospective study included 100 patients with BMs treated with HSRT between 2019 and 2023 as training dataset, while utilized medical images and clinical features from 40 patients from publicly available dataset PROTEAS project. Radiomic features were extracted from the contrast-enhancing BM (T1-weighted contrast-enhanced MRI) and edema (T2-FLAIR MRI). A baseline Cox proportional hazards model incorporating clinical variables was established for comparison. Three DeepSurv models were developed using different combinations of clinical, BM-derived, and edema-derived radiomic features. Model performance was evaluated using the concordance index (C-index). Kaplan-Meier analysis was performed for risk stratification, and Shapley Additive Explanations (SHAP) were used to identify the most influential prognostic features. Results: The best predictive performance was achieved by the DeepSurv model integrating clinical, BM-derived, and edema-derived radiomic features, outperforming the clinical-only Cox model (C-index: 0.61 vs. 0.72). The model effectively stratified patients into distinct prognostic groups with significantly different local failure-free survival outcomes ( Conclusion: A combination of clinical, tumor-derived, and edema-derived radiomic features predicted Local Progression-Free Survival more accurately than clinical variables alone. Peritumoral edema features contributed more strongly to local failure prediction than tumor features, highlighting the prognostic importance of the tumor microenvironment. Patients received targeted therapy with low-risk radiomic profiles benefit from HSRT for local control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.